Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice

Publication date: April 2016
Source:Critical Reviews in Oncology/Hematology, Volume 100
Author(s): Valentina Sini, Saverio Cinieri, Pierfranco Conte, Michelino De Laurentiis, Angelo Di Leo, Carlo Tondini, Paolo Marchetti
Current international guidelines recommend endocrine therapy as the initial treatment of choice in hormone receptor positive advanced breast cancer. Endocrine therapy has been a mainstay of hormone responsive breast cancer treatment for more than a century. To date it is based on different approaches,such as blocking the estrogen receptor through selective receptor estrogen modulators, depleting extragonadal peripheral estrogen synthesis by aromatase inhibitors or inducing estrogen receptor degradation using selective down-regulators.Despite estrogen and/or progesterone receptor positive status, up to a quarter of patients could be either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Different mechanisms, either intrinsic or acquired, could be implicated in endocrine resistance.In the present work available endocrine therapies and their appropriate sequences have been reviewed, and the most promising strategies to overcome endocrine resistance have been highlighted.



from Cancer via ola Kala on Inoreader http://ift.tt/1UyQqR8
via IFTTT